Future studies will be required to answer whether perilipin-2 is the aimed-for biomarker to confirm the presence of CPFs in patient plasma, to further explore the mechanism by which CPFs affect podocyte lipid metabolism and how this relates to pathogenesis of (recurrent) FSGS. Here, PLIN2 is linked to focal segmental glomerulosclerosis.